Profiling immunity to HIV vaccines with systems biology

Current Opinion in HIV and AIDS

Volumn 7, Issue 1, 2012, Pages 32-37

  Andersen Nissen, Erica ^a   Heit, Antje ^a   McElrath, M Juliana ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Assay standardization; Clinical trials; HIV vaccine; Systems biology

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

BLOOD SAMPLING; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; SYSTEM ANALYSIS; SYSTEMS BIOLOGY;

AIDS VACCINES; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; SYSTEMS BIOLOGY; THAILAND;

EID: 84857057946     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834ddcd9     Document Type: Review

References (51)

1. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010; 33:542-554.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
3. Zak DE, Aderem A. Systems biology of innate immunity. Immunol Rev 2009; 227:264-282.
4. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473:463-469.
5. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
6. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
7. Barnabas RV, Wasserheit JN, Huang Y, et al. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step Study). J Acquir Immune Defic Syndr 2011; 57:238-244
8. + T cells. Nat Med 2009; 15:876-878.
9. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15:873-875.
10. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 2010; 9:997-1005.
11. Munier CM, Andersen CR, Kelleher AD. HIV vaccines: progress to date. Drugs 2011; 71:387-414.
12. Ross AL, Brave A, Scarlatti G, et al. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis 2010; 10:305-316.
13. Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610-619. This HIV vaccine study found differing patterns of T-cell and antibody responses depending on whether participants received a DNA prime or a homologous MVA prime followed by MVA boost vaccine regimen.
14. + T cells toward a terminally differentiated effectormemory phenotype with cytotoxic potential, as contrasted with the response induced following homologous rAd5 priming.
15. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011; 6:e21225.
16. Spearman P, Lally MA, Elizaga M, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011; 203:1165-1173.
17. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011; 131:509-517.
18. Breen EC, Reynolds SM, Cox C, et al. A multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol 2011; 18:1229-1242.
19. Jackman RP, Utter GH, Heitman JW, et al. Effects of blood sample age at time of separation on measured cytokine concentrations in human plasma. Clin Vaccine Immunol 2011; 18:318-326.
20. Farrah T, Deutsch EW, Omenn GS, et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 2011; 10:M110.006353.
21. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009; 3:33-44.
22. Hu Z, Hood L, Tian Q. Quantitative proteomic approaches for biomarker discovery. Proteomics Clin Appl 2007; 1:1036-1041.
23. Pine SO, Kublin JG, Hammer SM, et al. Preexisting adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 2011; 6:e18526. This study found that Ad5-specific humoral immunity contributes significantly to vaccine-induced responses following vaccination with an rAd5 vector, and that certain factors in the T-cell response profile are associated with preexisting Ad5 neutralizing antibody titers.
24. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-444.
25. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106:4402-4407.
26. Cherian S, Levin G, Lo WY, et al. Evaluation of an 8-color flow cytometric reference method for white blood cell differential enumeration. Cytometry B Clin Cytom 2010; 78:319-328.
27. Nakaya HI, Wrammert J, Lee EK, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011; 12:786-795. This study proofed the utility of systems biology not only in the prediction of vaccine immunogenicity, but also it offered new insight into the molecular mechanism of efficacy of influenza vaccines.
28. Shen-Orr SS, Tibshirani R, Khatri P, et al. Cell type-specific gene expression differences in complex tissues. Nat Methods 2010; 7:287-289.
29. Bull M, Lee D, Stucky J, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007; 322:57-69. (Pubitemid 46560582)
30. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323:39-54. (Pubitemid 46722712)
31. Gill DK, Huang Y, Levine GL, et al. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 2010; 5:e14330.
32. Roederer M. Interpretation of cellular proliferation data: avoid the Panglossian. Cytometry A 2011; 79:95-101.
33. Spentzou A, Bergin P, Gill D, et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 2010; 201:720-729.
34. Pollara J, Hart L, Brewer F, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011; 79:603-612.
35. + T cells utilize preferential HLA alleles and target specific regions of HIV-1. J Acquir Immune Defic Syndr 2011; 58:248-252.
36. Rolland M, Tovanabutra S, deCamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17:366-371. In this genetic approach, HIV-1 sequences isolated from vaccine and placebo recipients who became infected with HIV-1 during the STEP study were compared to test for a 'sieve effect', to study the influence of immunization with MRKAd5 on the selection of viral variants capable of forming the founding HIV-1 population.
37. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-125.
38. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205:3119-3131.
39. + T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010; 16:1147-1151.
40. Duraiswamy J, Ibegbu CC, Masopust D, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 2011; 186:4200-4212.
41. Bomsel M, Tudor D, Drillet AS, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269-280.
42. McElrath MJ. Standing guard at the mucosa. Immunity 2011; 34:146-148.
43. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-223.
44. Kaltsidis H, Cheeseman H, Kopycinski J, et al. Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials. J Immunol Methods 2011; 370:43-54.
45. Mehra V, Musib R, Schito ML. Towards developing standardized protocols for evaluation of cellular mucosal immune responses - recommendations from a DAIDS/NIH workshop, June 15-16, 2009. Vaccine 2010; 28: 4689-4694.
46. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009; 6:20-28.
47. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-527.
48. Malaspina A, Rinaldo CR, Sekaly RP, et al. 'In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates', NIAID Workshop Report, Bethesda, August 4 2010. Vaccine 2011; 29:4647-4653.
49. + T cells retaining CD28. Blood 2011; 117:6542-6551.
50. Sui Y, Zhu Q, Gagnon S, et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci USA 2010; 107:9843-9848.
51. Rhee EG, Blattman JN, Kasturi SP, et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 2011; 85:315-323.